Author: Admin

Developer

BioSig Technologies (BSGM) – BioSig Announces Real World PURE EP Physician-Initiated Research

Posted on by Admin

Friday, July 22, 2022

BioSig Technologies (BSGM)
BioSig Announces Real World PURE EP Physician-Initiated Research

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(TM) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Announced study tests real-world AF patients.  BioSig announced yesterday a physician-initiated study. The research will study 30 patients with de novo paroxysmal atrial fibrillation (AF)  undergoing pulmonary vein isolation (PVI), with 6 month and 12 month follow-up. While the PURE EP 2.0 trial assessed PURE EP signal quality vs. current technology, this is the first real world study of patient outcomes. To date there have been few human trials that test the durability of PVI AF procedures. The study is officially registered at clincaltrials.gov NCT05464537 .

Kansas City Heart Rhythm Research Foundation is conducting the study.  Recall that Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center recently purchased the PURE EP System. Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas City Heart Rhythm Institute, is initiating this research protocol analyzing the signals acquired by the PURE EP System during RF ablation.  Long lasting, contiguous and deep enough ablation lesions have been and are a clinical challenge due to thickness of atrial tissue in different regions, as well as factors like the power and contact force of the ablation catheter.  AF ablation procedures might need to be repeated if the ablated tissue does not prevent recurrence of AF.  PURE EP signal processing will be reviewed for helping produce more durable, quicker and cost-effective outcomes….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Gevo Signs Sustainable Aviation Fuel Sales Agreement with American Airlines for 100 Million Gallons Per Year for Five Years

Posted on by Admin



Gevo Signs Sustainable Aviation Fuel Sales Agreement with American Airlines for 100 Million Gallons Per Year for Five Years

Research, News, and Market Data on Gevo

AGREEMENT
VALUED AT APPROXIMATELY $2.75 BILLION OVER FIVE YEARS

ENGLEWOOD, Colo., July 22, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) is pleased to announce a new fuel sales agreement with American Airlines, Inc. (NASDAQ: AAL). The agreement sets forth the terms for the sale of 100 million gallons per year of sustainable aviation fuel (SAF) for five years from Gevo’s future commercial operations. Gevo’s delivery of SAF under this agreement is expected to begin in 2026. Gevo estimates that the agreement should generate approximately $2.75 billion of revenue over the five-year term, inclusive of the value of environmental benefits. The Agreement with American Airlines is the single, largest fuel sales agreement ever entered into by Gevo with a customer.

American Airlines is a member of oneworld® global alliance (oneworld), and this agreement falls under the purview of memoranda of understanding (MoU) that oneworld members and Gevo signed earlier in 2022, laying the groundwork for the 14 world-class airlines in the alliance to purchase 200 million gallons of SAF per year, from Gevo’s future commercial operations. This SAF purchase agreement expands the list of committed airline partners and supports Gevo’s pursuit of its stated goal of producing and commercializing a billion gallons of SAF by 2030.

“The expansion of the global development of the SAF marketplace has reached an exciting point,” said Dr. Patrick R. Gruber, Gevo’s Chief Executive Officer. “While there is a tremendous amount of work to complete to bring all the critical elements of net-zero carbon SAF to the marketplace, our memoranda of understanding with oneworld alliance members and this subsequent commitment from American Airlines demonstrates the important momentum that is building for these types of products. I’m thrilled that Gevo is poised to continue to provide leadership for this product development.”

In September 2020, oneworld became the first global airline alliance to announce a target of carbon neutrality by 2050, establishing its commitment to long-term sustainability for the industry. The alliance followed up that commitment with an intermediate goal to achieve 10% SAF use across the member airlines by 2030.

“Today’s announcement is a historic step forward for American and our industry as we work to reduce our carbon footprint,” said Jill Blickstein, American’s Vice President of Sustainability. “The use of SAF is a cornerstone of our strategy to decarbonize air travel. While this landmark investment represents meaningful action by American Airlines, driving progress at the scale and pace we need requires critical policy action in Washington and at the State level. Alongside our 
oneworld partners, we’re proud to lead the way in the shift to SAF and make progress toward our shared climate goals.”

Further commenting on the agreement, Dr. Patrick R. Gruber, Chief Executive Officer of Gevo, said, “We are on a mission to drive greenhouse gasses out of the fuel supply chain with practical technology that can be scaled. In order to drive the GHG gasses out, we need renewable carbon and de-fossilized energy to power our production facilities. We know how to produce SAF. We know that by replacing fossil-based grid electricity with green electricity, replacing fossil-based natural gas with biogas, producing and using green hydrogen, and by working with farmers to improve the production of food while generating raw materials for SAF, we have a business system where incentives are aligned to improve sustainability and drive change. These take-or-pay SAF contracts help us show investors and lenders that this market is real, and merits investment to build plants for SAF. We are creating a new business system, one that can generate revenue for Gevo and attractive investment returns while also solving problems that impact all of us. By working together, we really can change the world. With these contracts in place, we hope to accelerate the journey.”

The agreement with American Airlines is subject to certain conditions precedent, including Gevo developing, financing, constructing and operating one or more production facilities to produce the SAF contemplated by the agreement. A copy of the agreement between American Airlines and Gevo will be filed with the U.S. Securities and Exchange Commission on Form 8-K no later than Friday, July 22, 2022.

About Gevo
Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business. Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI. Learn more at Gevo’s website: www.gevo.com

About
American Airlines Group
To Care for People on Life’s Journey®. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL and the company’s stock is included in the S&P 500. Learn more about what’s happening at American by visiting news.aa.com and connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.

Forward-Looking
Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including the agreement with American Airlines, Gevo’s ability to produce SAF, Gevo’s estimate of the revenue that might be generated from the agreement with American Airlines, the assumptions used to estimate potential revenue from the agreement, including, but not limited to future pricing of commodities and the future values of certain environmental benefits, Gevo’s technology, Gevo’s ability to develop, finance, construct and operate production facilities to produce SAF, the attributes of Gevo’s products, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Media
Contact
Heather L. Manuel
+1 303-883-1114
IR@gevo.com


Tokens.com Corp. (SMURF) – Hulk Labs is Getting Stronger

Posted on by Admin

Thursday, July 21, 2022

Tokens.com Corp. (SMURF)
Hulk Labs is Getting Stronger

Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Financing. Tokens.com’s management announced subsidiary Hulk Labs has completed a strategic financing round led by DV Investment Management. The total amount for the round was $750,000, with the pre-money valuation for Hulk Labs being at $8 million, according to management. The Company is participating in the round and will continue to own over 90% of the subsidiary. DV Investment Management represented themselves in the financing round.

Who is DV Investment Management? DV Investment Management is an affiliate of the DV Group of financial services companies, and serves as an independent proprietary trading firm. DV Group affiliates include two broker-dealers, a cryptocurrency market making firm, and a bourgeoning investment adviser….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Leading Technology Provider Selects Harte Hanks’ Audience Finder(TM) to Identify Interested Prospects

Posted on by Admin



Leading Technology Provider Selects Harte Hanks’ Audience Finder(TM) to Identify Interested Prospects

Research, News, and Market Data on Harte Hanks

CHELMSFORD, MA / ACCESSWIRE / July 21, 2022 / Harte Hanks Inc. (NASDAQ:HHS), a leading global customer experience customer experience company focused on bringing companies closer to customers for nearly 100 years, announced today that it was selected by a leading business technology company, to support and enhance their B2B marketing campaigns using Harte Hanks proprietary technology.

Harte Hanks’ proprietary Audience Finder™ solution identifies in-market prospects that are signaling interest all while respecting privacy and consumer choice.

Janel Harris, Managing Director, Harte Hanks comments, “Our client is widely respected for their global technology products and services, but they challenged us to help them identify and engage with potential customers whose digital journey revealed a strong intent to purchase.”

Audience Finder
™ further enhances the customer data by leveraging Harte Hanks’ proprietary DataView product. DataView is a multi-sourced database used to provide 3rd party data to augment a client’s data files to ensure a comprehensive understanding of prospects and customers.

According to Don Aicklen, SVP Sales & Marketing Harte Hanks. “Harte Hanks has a variety of proprietary solutions and will continue to develop solutions like Audience Finder™ to improve our clients’ ability to effectively reach their prospects. The combination of Audience Finder and DataView delivered a significant increase in marketing campaign performance by generating more qualified leads.”

About Harte Hanks:

Harte Hanks (NASDAQ:HHS) is a leading global customer experience company whose mission is to partner with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.

Using its unparalleled resources and award-winning talent in the areas of Customer Care, Fulfillment and Logistics, and Marketing Services, Harte Hanks has a proven track record of driving results for some of the world’s premier brands, including Bank of America, GlaxoSmithKline, Unilever, Pfizer, HBOMax, Volvo, Ford, FedEx, Midea, Sony and IBM among others. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,500 employees in offices across the Americas, Europe, and Asia Pacific.

For more information, visit hartehanks.com

For media inquiries, contact Jennifer London at Jen.London@HarteHanks.com

SOURCE: Harte Hanks, Inc.

 

Release – U.S. Enterprises Committing to IoT With Long-Term Plans

Posted on by Admin



U.S. Enterprises Committing to IoT With Long-Term Plans

Research, News, and Market Data on Information Services Group

Companies
want both a future vision and short-term results, with goals for visibility,
data analytics and security, ISG Provider Lens™ report says

STAMFORD, Conn.–(BUSINESS WIRE)– U.S. enterprises investing in the Internet of Things (IoT) increasingly are starting out with long-term strategies instead of just discrete proofs of concept, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.

The 2022 ISG Provider Lens™ Internet of Things — Services and Solutions report for the U.S. finds a growing number of U.S. organizations want to develop a high-level view of their IoT future while achieving immediate, measurable benefits from the technology.

“Enterprise IoT plans are growing more ambitious,” said John Lytle, industrial manufacturing client lead for ISG in the Americas. “Companies are looking to optimize their operations, address security threats and extract insights from IoT data.”

Advances in AI and machine learning have expanded the possibilities of IoT analytics, ISG says. In its most basic form, IoT gives enterprises visibility into their operations by collecting data from sensors in machine tools, vehicles and other assets. That data can be used in real time to track objects, generate alerts or predict failures. Using analytics tools, managed services providers are now using the same data sources to derive higher-level business insights.

As in most IT fields today, both enterprises and service providers face a tight market for qualified professionals who can design, integrate and operate complex IoT systems, the report says. Providers and clients are opening delivery centers in Eastern Europe, Latin America and Asia Pacific to spread out the risk of attrition beyond established centers in India.

“Managed IoT services are most affected by the skills shortage,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Providers are responding with recruitment, training and intelligent automation.”

Enterprises are seeking plug-and-play interoperability among devices, software and networks so they can respond to future requirements and avoid vendor lock-in, but this remains a challenge, ISG says. To deliver maximum value, an enterprise’s IoT infrastructure often needs to be customized to work with specific telecom networks and hyperscale cloud platforms. Yet a lengthy integration process can cut into a project’s return on investment. Providers are continuing efforts to offer open platforms and smooth integration services.

The 2022 ISG Provider Lens™ Internet of Things — Services and Solutions report for the U.S. evaluates the capabilities of 33 providers across five quadrants: Strategy Consulting, Implementation and Integration, Managed Services, Mobile Asset Tracking and Management, and Data Management and AI on the Edge.

The report names Atos, Capgemini, Cognizant and HCL as Leaders in all five quadrants. It names HARMAN DTS and IBM as Leaders in four quadrants each and Accenture and Siemens as Leaders in three quadrants each. Verizon is named as a Leader in two quadrants, and Bosch, Infosys, LTTS, PwC, TCS and Wipro are named as Leaders in one quadrant each.

In addition, Hitachi Vantara is named as a Rising Star — a company with a “promising portfolio” and “high future potential” by ISG’s definition — in two quadrants. Cyient, eInfochips, HARMAN DTS, HPE, NTT and TCS are named as Rising Stars in one quadrant each.

Customized versions of the report are available from Cyient and PwC.

The 2022 ISG Provider Lens™ Internet of Things — Services and Solutions report for the U.S. is available to subscribers or for one-time purchase on this webpage.

About
ISG Provider Lens™ Research

The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

A companion research series, the ISG Provider Lens Archetype reports, offer a first-of-its-kind evaluation of providers from the perspective of specific buyer types.

About
ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 800 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

Source: Information Services Group, Inc.

 

Release – BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm Institute

Posted on by Admin



BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm Institute

News and Market Data on BioSig Technologies

Led by Dhanunjaya DJ Lakkireddy, MD., the study will investigate expanded applications for the signals acquired by BioSig’s PURE EP(T.M.) System

Westport, CT, July 21, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas City Heart Rhythm Institute, will initiate a research protocol analyzing the signals acquired by the PURE EP(T.M.) System during Radiofrequency (RF) ablation.

The single center study at Overland Park Regional Medical Center and officially registered with clinicaltrials.gov [NCT05464537], will include 30 participants with paroxysmal atrial fibrillation (AF) undergoing pulmonary vein isolation (PVI). The study aims to build on previous research that claims the loss of the negative component of the unipole during PVI can serve as a tool for achieving durability with overall lesser procedure time and no significant increase in adverse events.  AF recurrence will be examined at 6 and 12-months post-procedure.

“Positive results from this study could substantially emphasize the value of the PURE EP System in the EP lab by decreasing procedural cost specific to both time and product spend,” commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc.

Dr. Lakkireddy is a board-certified, fellowship-trained cardiologist specializing in electrophysiology. With more than 15 years of experience, he has specialized interest in complex arrhythmia management for all types of arrhythmias conditions. The Company recently announced that Overland Park Regional Medical Center (OPRMC) has signed an agreement to purchase the Pure EP(T.M.) System under the terms of the Company’s new leasing program. This represents BioSig’s first national purchasing agreement since announcing The Company’s new commercial structure and clinical support teams.

About The Kansas City
Heart Rhythm Institute
The Kansas City Heart Rhythm Institute brings the highest quality clinical care, research and arrhythmia education to Kansas City and the surrounding area. With eight practicing Electrophysiologists, the Kansas City Heart Rhythm Institute has three Electrophysiology clinics in the greater Kansas City area as well as outreach locations in four major hospitals.

About Overland Park
Regional Medical Center
Overland Park Regional Medical Center is a licensed 343-bed facility offering acute medical care services to patients. Cardiovascular programs at OPRMC have received certification from The American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR). OPRMC’s clinician and physician experts excel in a wide range of interventional cardiology practices and complex electrophysiology procedures, including Complex Arrhythmia Management (AF, VTACH, PVC, SVT), Convergent AF Ablation (with C.T. surgeon and E.P.), Leadless Pacemakers & Internal Cardiac Defibrillators, and Left Atrial Appendage Closure.

About BioSig
Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(T.M.) System, is a novel signal processing and acquisition platform designed to extract advanced diagnostic and therapeutic data that enhances physician workflow and increases throughput. PURE EP(T.M.) was engineered to address the limitations of existing EP technologies by empowering physicians with superior signals and actionable insights.

The Company is in a national commercial launch of the PURE EP(T.M.) System. The technology is in regular use in some of the country’s leading centers of excellence, including 
Mayo Clinic, and Texas Cardiac Arrhythmia Institute at St.
David’s Medical Center.

Clinical data acquired by the PURE EP(T.M.) System in a multi-center study at centers of excellence including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center  was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the 
Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(T.M.) signals over conventional sources.

Forward-looking
Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market conditions and the Company’s intended use of proceeds, (ii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of our competition; (vi) loss of one or more key executives or scientists; and (vii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Andrew Ballou

BioSig Technologies, Inc.

Vice President, Investor Relations

55 Greens Farms Road, 1st Floor

Westport, CT 06880

aballou@biosigtech.com

203-409-5444, x13

Primary Logo

Source: BioSig Technologies, Inc.

Released July 21, 2022

 


Release – Entravision Expands Digital Partnership with Meta in Honduras and El Salvador Bringing Latin American Partnership to 11 Countries

Posted on by Admin



Entravision Expands Digital Partnership with Meta in Honduras and El Salvador Bringing Latin American Partnership to 11 Countries

Research, News, and Market Data on Entravision

Expansion brings
Entravision’s presence to a total of 18 countries in Latin America  

Entravision Cisneros Interactive will provide support and consulting
services to promote the commercial objectives of local businesses in the region

SANTA MONICA, Calif.–(BUSINESS WIRE)– Entravision (NYSE: EVC), a leading global advertising solutions, media and technology company, today announced that it has become the Authorized Sales
Partner of Meta, the company that owns the Facebook, Instagram and WhatsApp platforms, in Honduras and El Salvador. Through its business unit, Entravision Cisneros Interactive, Entravision will provide support, consulting, training and billing in local currency to help businesses achieve their advertising goals.

“We are very pleased to expand our alliance with Meta into Honduras and El Salvador, further strengthening our partnership and foothold in Latin America,” said Byron Cabrera, Country Manager of Honduras and El Salvador for Entravision Cisneros Interactive. “This expansion within Latin America will enable us to continue our mission of providing companies with strategic support, creative expertise and content development that facilitates the use of new tools which take full advantage of all that the Meta suite has to offer and are geared toward boosting their business in the region.”

Entravision Cisneros Interactive, as an Authorized Sales Partner, will focus on helping local businesses grow sales while at the same time deploy their advertising investments more efficiently. The new offices in Honduras and El Salvador join the 16 existing markets in Latin America in which the company already has a successful presence.

Commenting on this track record of success, Victor Kong, CEO of Entravision Cisneros Interactive, noted, “Our expansion throughout Latin America is a direct result of the progress we have delivered in the region over the past five years. In 2021, we trained more than 5,000 people, including advertisers and agencies, to leverage the Meta platform. This educational investment has allowed us to help advertisers increase their sales, minimize their customer service expenses and reduce their cancellation rates, along with many other core business objectives. It is this experience that provides us with the utmost confidence that we will achieve a similar impact on companies in Honduras and El Salvador by extending the top-notch experience we provide to our other clients in Latin America.”

“Meta is dedicated to expanding our stronghold in Latin America, and the expansion of our alliance with Entravision Cisneros Interactive in Honduras and El Salvador is a key sign of our commitment to the region,” said Christian Pretelt, Regional Reseller Leader for Meta in Latin America. “We are very excited to extend the reach of this successful program, helping advertisers and agencies create more meaningful connections with their consumers. As part of our collaboration, we will also implement digital marketing education programs to drive growth in Central America, instilling processes that will position companies to drive their short- and long-term business goals.”

About Entravision

Entravision is a leading global advertising solutions, media and technology company connecting brands to consumers. Our dynamic portfolio includes digital, television and audio offerings. Digital, our largest revenue segment, is comprised of four business units: our digital sales representation business; Smadex, our programmatic ad purchasing platform; our branding and mobile performance solutions business; and our digital audio business. Through our digital sales representation business, we connect global media companies such as Meta, Twitter, TikTok and Spotify with advertisers in primarily emerging growth markets worldwide. Smadex is our mobile-first demand side platform, enabling advertisers to execute performance campaigns using machine learning. We also offer a branding and mobile performance solutions business, which provides managed services to advertisers looking to connect with global consumers, primarily on mobile devices, and our digital audio business provides digital audio advertising solutions for advertisers in the Americas. In addition to digital, Entravision has 49 television stations and is the largest affiliate group of the Univision and UniMás television networks. Entravision also manages 46 primarily Spanish-language radio stations that feature nationally recognized, Emmy award-winning talent. Shares of Entravision Class A Common Stock trade on The New York Stock Exchange under the ticker symbol: EVC. Learn more about all of our media, marketing and technology offerings at entravision.com or connect with us on LinkedIn and Facebook.

About Entravision Cisneros Interactive

Entravision-Cisneros Interactive, a business unit of Entravision, is the leading digital advertising company serving Latin America. The company has an active presence in 18 countries, leveraging unique commercial partnerships with Meta, Spotify, LinkedIn, Anzu and other leading media and technology platforms. In addition, the company offers Audio.Ad, Latin America’s leading digital audio ad network, with more than 350 publishers through a full solution technology stack offering, and Justmob, the leading mobile marketing company with global reach.

Forward Looking Statements

This press release contains certain forward-looking statements. These forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this press release. Although the Company believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that actual results will not differ materially from these expectations, and the Company disclaims any duty to update any forward-looking statements made by the Company. From time to time, these risks, uncertainties and other factors are discussed in the Company’s filings with the Securities and Exchange Commission.

Investors
Christopher T. Young
Chief Financial Officer
310-447-3870

Kimberly Esterkin

Addo Investor Relations
evc@add.com
310-829-5400

Source: Entravision


Understanding Drug Names – There is a Methodology

Posted on by Admin 

Image Credit: Diverse Stock Photos (Flickr)


Why are Drug Names So Long and Complicated? A Pharmacist Explains the Logic Behind the Nomenclature

At some point in your life, you’ll likely find yourself with a prescription from your doctor to fill. While it’s important to keep track of all the medications you’re taking, that can be hard to do when the names of so many of these drugs are difficult to pronounce and even harder to remember.

This article was republished with permission from The Conversation, a news
site dedicated to sharing ideas from academic experts. It was written by and
represents the research-based opinions of Jasmine Cutler, Assistant
Professor of Pharmacotherapeutics, University of South Florida

In my role as a pharmacist, I’ve helped countless patients figure out exactly which medication they were taking for what ailment. Some wonder why they were prescribed the medication in the first place, or need help differentiating between drugs with names that seem like complete gibberish.

But there is a rhyme and a reason to drug names. All prescribed medications follow a standard nomenclature that describes what the drug is made of and how it functions.


Who Names Drugs?

Drugs get both a brand, or proprietary, name and a generic name that is nonproprietary. Each is assigned in a slightly different process.

As long as a drug compound isn’t trademarked, drug companies decide on a proprietary brand name for the medications they sell. Usually the brand name relates to the conditions the drug is intended to treat and is easy for both providers and patients to remember but doesn’t follow a standardized naming guideline. For example, the drug Lopressor helps lower blood pressure.

On the other hand, generic drug names all follow a standard nomenclature that helps medical providers and researchers more easily recognize and classify the drug. Lopressor, for example, has a generic name of metoprolol tartrate. The U.S. Adopted Names Council, composed of representatives from the Food and Drug Administration, American Medical Association, U.S. Pharmacopeia and American Pharmacists Association, works with the World Health Organization to assign international nonproprietary names, or INNs, to drug compounds. Similar organizations exist internationally.

A globally recognized naming process makes an otherwise confusing name game more manageable. It helps the medical community easily learn and categorize newly approved medications and reduce prescribing errors by providing a unique, standard name that reflects each active ingredient in the drug.

For example, several Type 2 diabetes medications fall under one class called glucagon-like peptide-1 (GLP-1) receptor agonists. Although all medications in this class have different brand names, each of the generic versions ends in the suffix “-tide.” This helps health providers identify all the drugs that belong to this medication class. A few examples include Byetta (exenatide), Trulicity (dulaglutide) and Victoza (liraglutide).

 

How are Generic Drug Names Assigned?

The naming process starts when a drug company submits an application to the U.S. Adopted Names Council with a proposed generic name. USAN considers a number of factors when evaluating a name, such as whether it relates to how the drug works, how translatable it is to other languages and whether it is easy to say. In general, the name should be simple – fewer than four syllables long – and should not be easily confused with other existing generic drugs.

Once a name is agreed upon by USAN and the drug company, it is then proposed to the INN Expert Group. Sponsored by the World Health Organization, the INN Expert Group is composed of global specialists who represent the pharmaceutical, chemical, pharmacological and biochemical sciences. They may either accept the proposed name or suggest an alternative. Once the drug company, USAN and the INN Expert Group come to an agreement about a name, it is placed in the WHO Drug Information journal for four months for public comments or objections before final adoption.

 

What’s in a Generic Drug Name?

Generic names follow a prefix-infix-stem system. The prefix helps distinguish a drug from other drugs in the same class. The infix, used more occasionally, further subclassifies the drug. The stem at the very end of the name indicates the drug’s function and marks its place within the name game.

Stems are composed of one or two syllables that describe a drug’s biological effects as well as its physical and chemical qualities and structure. Drugs with the same stem share features like the conditions they treat and how they work in the body. The WHO publishes a regularly updated stem book to keep everything in line.

For example, the stem “-prazole” indicates that the drug is chemically related to a class of compounds called benzimidazoles that have similar functions. As a result, drugs such as lansoprazole (Prevacid), esomeprazole (Nexium) and omeprazole (Prilosec) all treat acid reflux, ulcers and heartburn. The “e” prefix of esomeprazole differentiates it from omeprazole, which has a slightly different chemical structure.

Another common example is drugs that use the stem “stat,” which means enzyme inhibitors. Atorvastatin (Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor) all belong to the same class of inhibitors that block a key enzyme in the body’s cholesterol production process. As a result, these cholesterol-reducing “statins” are used to prevent cardiovascular conditions like heart attack and stroke.

 

Are There Exceptions to the Name Game?

Although generic names stay consistent, there have been multiple changes to brand names over the past couple of decades after increases in prescribing and dispensing errors. Some examples include the acid reflux and stomach ulcer drug omeprazole, which was rebranded from Losec to Prilosec because it was frequently confused with the diuretic Lasix. Another example is when the antidepressant Brintellix was changed to Trintellix because it was commonly confused with the blood thinner Brilinta.

Some generic medications may work at multiple targets in the body and be used for multiple conditions. For example, drugs with the stem “-afil,” such as tadalafil (Cialis), sidenafil (Viagra) and vardenafil (Levitra), belong to a class of drugs that relax smooth muscle and widen the blood vessels. Although commonly prescribed for erectile dysfunction, they can also be used to treat pulmonary arterial hypertension, a specific type of elevated blood pressure that affects the arteries in the heart and lungs.

In addition, nomenclature guidelines
aren’t set in stone, and the U.S. Adopted Names Council anticipates that they
will continue to change as newer, more complex substances are discovered, developed
and marketed.

For example, a rise in the number of drugs developed with different salts and esters has led to the use of a modified naming process to incorporate the inactive parts of the compound.

As you can guess, it takes health care providers countless months and years to learn and understand this naming process. We are taught the science behind each chemical structure and how it works, which makes it easier to know the rules of the name game. But for those without a background in chemistry and biology, it can be like reading a foreign language.

There are several resources that can help you navigate the drug name game, however. Ask your health care provider or pharmacist if you have questions about how your medication works or what it is used for. They are generally a phone call or visit away.


Suggested Content



Biotech Stocks Outperformance Factors – Will they Continue?

The Netflix Model for Pharmaceuticals





Giving Old Drugs New Purpose to Meet Unmet Needs

What is the Approval Process for Medical Devices?

Stay up to date. Follow us:

 

Release – NexusBioAg and MustGrow Biologics Announce Exclusive Marketing and Distribution Agreement in Canada

Posted on by Admin



NexusBioAg and MustGrow Biologics Announce Exclusive Marketing and Distribution Agreement in Canada

Research, News, and Market Data on MustGrow Biologics

Collaboration expands
innovative, sustainable and regenerative farming solutions for Canadian growers

Downers Grove, ILL. & SASKATOON, SASK. — July 20, 2022 — Univar Solutions Inc. (NYSE: UNVR) (“Univar
Solutions“),  a leading global solutions provider to users of specialty ingredients and chemicals, announced today that NexusBioAg, a division of Univar Solutions, and MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FRA: 0C0) (“MustGrow“), an agricultural biotechnology company focused on providing science-based biological solutions for high-value crops, have reached an exclusive marketing and distribution agreement in the Canadian canola and pulse market for TerraMG™, a mustard-derived soil biopesticide technology. The addition of this plant-based technology further diversifies and expands NexusBioAg’s extensive portfolio of inoculants, micronutrients, nitrogen stabilizers and foliars for the Canadian agricultural market.

In 2021, NexusBioAg and MustGrow initiated a field research program to develop MustGrow’s sustainable farming technology in Canadian canola and pulse crops. This technology has the potential to address the agronomic challenges of ClubRoot and Aphanomyces diseases which impact these crops. Building on the past data, the companies now are moving forward to the next stage of the development process. Through this exclusive marketing and distribution agreement, NexusBioAg customers have access to the latest in agronomic innovation, which is yet to be registered with Canada’s Pest Management Regulatory Agency.

“TerraMG complements the NexusBioAg portfolio and we are excited to add this technology to our growing product offering. As the sole distributor of TerraMG in Canada for use in canola and pulse crops, this agreement further reinforces NexusBioAg’s commitment to collaborating with leading manufacturers to launch innovative, sustainable and cutting-edge solutions that provide value to the Canadian agricultural industry and benefit its growers,” said Matthew Ottaway, senior vice president, global consumer solutions for Univar Solutions.

NexusBioAg is committed to launching innovative, cutting-edge products, with a focus on sustainability and regenerative agriculture, which benefit the Canadian agricultural industry and growers. MustGrow specializes in the research and development of organic biopesticides, harnessing the mustard seed’s natural defense mechanism with a technology that has the potential to control diseases, pests and weeds. Combining the proficiencies of both companies in the agriculture market will help Canadian growers benefit from innovative and sustainable farming solutions.

“We are very pleased to partner with an organization like NexusBioAg. Their team’s technical and commercial expertise is unparalleled and will be advantageous in accelerating the development and growth of TerraMG for use in Canadian canola and pulse crops. The NexusBioAg team has tremendous knowledge of the Canadian agriculture market as well as sustainable farming solutions. We look forward to commercializing this biopesticide technology in the Canadian market together,” remarked MustGrow COO Colin Bletsky.

For more information about NexusBioAg’s crop nutrition solutions, please visit nexusbioag.com. To learn more about TerraMG™, visit mustgrow.ca.

About Univar Solutions
Univar Solutions (NYSE: UNVR) is a leading global chemical and ingredient distributor representing a premier portfolio from the world’s leading producers. With the industry’s largest private transportation fleet and technical sales force, unparalleled logistics know-how, deep market and regulatory knowledge, formulation and recipe development, and leading digital tools, Univar Solutions is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. While fulfilling its purpose to help keep communities healthy, fed, clean and safe, Univar Solutions is committed to helping customers and suppliers innovate and focus on Growing Together. Learn more at univarsolutions.com.

About NexusBioAg
Univar Solutions’ NexusBioAg provides an expanded portfolio of crop nutrition solutions, including industry-leading inoculants, micronutrients, nitrogen stabilizers, and foliar products. With a diverse collection of inventory and logistics experts, procurement, customer service, agronomists, and sales and marketing experts, NexusBioAg strives to help meet increasingly unique agricultural businesses’ needs. Through these best-in-class capabilities, a collaborative team-oriented approach, and a commitment to agricultural integrity, NexusBioAg is helping customers innovate and grow. Learn more at NexusBioAg.com.

About MustGrow
MustGrow is an agriculture biotech company developing organic biopesticides and bioherbicides by harnessing the natural defense mechanism of the mustard plant to protect the global food supply from diseases, insect pests, and weeds. MustGrow and its leading global partners — Janssen (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Over 100 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection. Pending regulatory approval, MustGrow’s patented liquid products could be applied through injection, standard drip or spray equipment, improving functionality and performance features. Now a platform technology, MustGrow and its global partners are pursuing applications in several different industries from preplant soil treatment and weed control, to postharvest disease control and food preservation. MustGrow has approximately 49.2 million basic common shares issued and outstanding and 55.1 million shares fully diluted. For further details please visit mustgrow.ca.  

Univar Forward-Looking Statements
This press release includes certain statements relating to future events and Univar Solutions’ intentions, beliefs, expectations, and predictions for the future, which are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond Univar Solutions’ control. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the expectations and assumptions. A detailed discussion of these factors and uncertainties is contained in Univar Solutions’ filings with the Securities and Exchange Commission. Potential factors that could affect such forward-looking statements include, among others: the ultimate geographic spread of the COVID-19 pandemic; the duration and severity of the COVID-19 pandemic; actions that may be taken by governmental authorities to address or otherwise mitigate the impact of the COVID-19 pandemic; the potential negative impacts of COVID-19 on the global economy and Univar Solutions’ customers and suppliers; the overall impact of the COVID-19 pandemic on Univar Solutions’ business, results of operations and financial condition; other fluctuations in general economic conditions, particularly in industrial production and the demands of Univar Solutions’ customers; significant changes in the business strategies of producers or in the operations of Univar Solutions’ customers; increased competitive pressures, including as a result of competitor consolidation; significant changes in the pricing, demand and availability of chemicals; Univar Solutions’ levels of indebtedness, the restrictions imposed by Univar Solutions’ debt instruments, and Univar Solutions’ ability to obtain additional financing when needed; the broad spectrum of laws and regulations that we are subject to, including extensive environmental, health and safety laws and regulations; an inability to integrate the business and systems of companies we acquire, including of Nexeo Solutions, Inc., or to realize the anticipated benefits of such acquisitions; potential business disruptions and security breaches, including cybersecurity incidents; an inability to generate sufficient working capital; increases in transportation and fuel costs and changes in Univar Solutions’ relationship with third party providers; accidents, safety failures, environmental damage, product quality and liability issues and recalls; major or systemic delivery failures involving Univar Solutions’ distribution network or the products we carry; operational risks for which we may not be adequately insured; ongoing litigation and other legal and regulatory risks; challenges associated with international operations; exposure to interest rate and currency fluctuations; potential impairment of goodwill; liabilities associated with acquisitions, ventures and strategic investments; negative developments affecting Univar Solutions’ pension plans and multi-employer pensions; labor disruptions associated with the unionized portion of Univar Solutions’ workforce; and the other factors described in Univar Solutions’ filings with the Securities and Exchange Commission. We caution you that the forward-looking information presented in this press release is not a guarantee of future events or results and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “plan,” “seek,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe” or “continue” or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and Univar Solutions does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise, except as required by law.

MustGrow Forward-Looking Statements
Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: (i) potential product approvals; (ii) anticipated actions by partners to drive field development work including dose rates, application frequency, application methods, and the regulatory work necessary for commercialization; (iii) expected product efficacy of MustGrow’s mustard-based technologies; and (iv) expected outcomes from collaborations with commercial partners.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the preferences and choices of agricultural regulators with respect to product approval timelines; (ii) the ability of MustGrow’s partners to meet obligations under their respective agreements; and (iii) other risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2021 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

© 2022 MustGrow Biologics Corp. All rights reserved. 

 


How Bad Will the Housing Market Correction Be?

Posted on by Admin 



Image Credit: Dave Morgan (Pexels)


The Winds are Changing for Housing, How Long Can Prices Remain High?

Is the Housing market in a correction? Corrections, although unpleasant if your long the asset class, are viewed as normal and healthy. Home values have been climbing for a while. The forces that helped drive other markets higher over the past few years were also at work pushing residential properties up at an unsustainable pace. This year the stock and bond markets have come off of their steamy highs, it appears real estate and housing are setting up to do the same.

On Tuesday (July 19), it was reported by the National Association of Home Builders (NAHB)  that Single Family Starts fell to a two year low of 2%. This came just one day after it was reported that home builder confidence dropped by a steep 12 points to 55 in July. That separate report was a release of the National Association of Home Builders/Wells Fargo Housing Market Index. Sentiment has accelerated downward since December when it stood at 84 (based on 100). It is now at its lowest level since May 2020 and faced with tighter money conditions going forward.

In addition to tighter money (ie, higher mortgage rates), housing headwinds include building material supply chain bottlenecks and elevated construction costs. According to the NAHB, for the first time since June 2020, both single-family starts and permits fell below a 1 million annual pace.


Housing Starts

By falling 2%, housing starts were at a seasonally adjusted annual rate of 1.56 million units in June, according to the U.S. Department of Housing and Urban Development and the U.S. Census Bureau. The June reading of 1.56 million starts is the number of housing units builders would begin if development kept the current pace for the next 12 months. Using this overall number, single-family starts decreased 8.1% to a 982,000 seasonally adjusted annual rate. This is the lowest single-family starts pace since June 2020. Multifamily dwellings, which include apartment buildings and condos, were on the upswing; this sector increased 10.3% an annualized 577,000 pace.

“Single-family starts are retreating on higher construction costs and interest rates, and this decline is reflected in our latest builder surveys, which show a steep drop in builder sentiment for the single-family market,” said Jerry Konter, chairman of the National Association of Home Builders (NAHB). By itself, fewer homes being built and entering the market could be bullish for home sales, but the reason for the slowdown, according to Mr. Konter, is “Builders are reporting weakening traffic as housing affordability declines.”

NAHB Chairman Konter said 13% of builders who participated in the monthly survey said they had reduced home prices over the last month to lure buyers.

Rober Dietz, the chief economist at the NAHB said, “While the multifamily market remains strong on solid rental housing demand, the softening of single-family construction data should send a strong signal to the Federal Reserve that tighter financial conditions are producing a housing downturn. Dietz is concerned that supply may not match needs, “Price growth will slow significantly this year, but a housing deficit relative to demographic need will persist through this ongoing cyclical downturn.”

Regionally and on a year-to-date basis, combined single-family and multifamily starts are 4.4% lower in the Northeast, 4.7% higher in the Midwest, 11.1% higher in the South, and 0.4% lower in the West.


Housing Permits

Overall, permits to build a new home decreased 0.6% in June. Single-family permits decreased 8.0%. This is the lowest pace for single-family permits since June 2020. Multifamily permits again increased by 11.5% to an annualized 718,000 pace.

Regional permit data on a year-to-date basis, permits are 5.1% lower in the Northeast, 2.5% higher in the Midwest, 2.9% higher in the South, and 3.0% higher in the West.


Interest Rates

The average contract interest rate on a 30-year fixed-rate mortgage climbed to 5.51% for the week ending on July 14. The same rate was just below 3% one year earlier.

 

Take Away

The NAHB indicated a drop in confidence within the housing market due to the impact of high inflation on building costs and rising interest rates. This has resulted in “dramatically slowing sales and buyer traffic.”

Mortgage rate increases come at a time when houses are still at or near their highs from the surge experienced during the pandemic. The housing “correction” could bring monthly costs of owning a home in line with what they had been prior to recent mortgage rate increases. This would mean prices low enough to equate to the same monthly outlay to the buyer. Should the economy weaken further, there is the potential for home prices to decline further.

All markets impact the others. When housing prices rise, people feel better about their financial situation. Owners also find it easier to borrow against their home’s appreciation. The economy and stock markets all tend to do better. Home prices have remained near their highs, a shallow correction might be welcome to those that are just now looking to enter the market for a home.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



What Will It Take to End Rampant Home-Price Inflation?

Avoiding the Noise and Focusing on Managing Your Investments




The Soft Landing Challenge, Fed Chairman Makes No Promises

US Dollar Strength, Commodities Weakness, and Fed Resolve


Stay up to date. Follow us:

 

Release – TheStreet Partners With QuoteMedia to Advance Stock Research Tools and Streaming Solutions

Posted on by Admin



TheStreet Partners With QuoteMedia to Advance Stock Research Tools and Streaming Solutions

Research, News, and Market Data on QuoteMedia

PHOENIX, July 20, 2022 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, announces today that they have partnered with The Arena Group (NYSE American: AREN) to provide financial market data and hosted content visualizations for their flagship financial destination, TheStreet.com .

To enhance access for a younger and more diverse reader, QuoteMedia’s QMod Suite of responsive market data widgets will integrate data and content across TheStreet.com while optimizing the display for viewing on all types of desktop and mobile devices. Licensed QuoteMedia content includes Equities, Options, Funds and Global Indices data, as well as a wide array of News, Fundamentals, Charting, Analytics and Transactional Portfolio modules to assist in managing TheStreet.com’s subscription products.

“TheStreet.com is one of the most important financial destinations in the world, and it has been for over 20 years,” said Dave Shworan, CEO of QuoteMedia Ltd. “It has been a trusted source of reliable, informative and objective business news and market analysis for decades. Having TheStreet choose QuoteMedia as their data provider is gratifying for our company, and we are very excited to be working with them.”

About The Arena Group
The Arena Group creates robust digital destinations that delight consumers with powerful journalism and news about the things they love – their favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. With powerful technology, editorial expertise, data management, and marketing savvy, the transformative company enables brands like Sports Illustrated, TheStreet and Parade to deliver highly relevant content and experiences that consumers love. To learn more, visit www.thearenagroup.net.

About TheStreet
TheStreet is a leading digital financial media company. We provide our readers and advertisers with a variety of subscription-based and advertising-supported content and tools through a range of online platforms, including websites, mobile devices, email services, widgets, blogs, podcasts and online video channels.

Media Contacts:
Rachael Fink
Public Relations Manager, The Arena Group
Rachael.Fink@thearenagroup.net

About QuoteMedia
QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Broadridge Financial Systems, JPMorgan Chase, CI Financial, Canaccord Genuity Corp., Hilltop Securities, HD Vest, Stockhouse, TheStreet.com, Zacks Investment Research, The Motley Fool, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, FolioFN, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Qtrade Financial, CNW Group, IA Private Wealth, Ally Invest, Inc., Suncor, Virtual Brokers, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Cirano, Equisolve, Stock-Trak, Mergent, Cision, Day Trade Dash and others. Quotestream®, QMod™ and Quotestream Connect™ are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com .

QuoteMedia Investor Relations
Brendan Hopkins
Email: investors@quotemedia.com
Call: (407) 645-5295

Primary Logo

News Provided by GlobeNewswire via QuoteMedia


Release – Growth Of Direct Digital Holdings’ Colossus SSP Reflects Strong Results Generated For Multicultural And General Market Publishers and Leading Brands

Posted on by Admin



Growth Of Direct Digital Holdings’ Colossus SSP Reflects Strong Results Generated For Multicultural And General Market Publishers and Leading Brands

Research, News, and Market Data on Direct Digital Holdings

SSP Kicked Off
2022 With Significant Revenue Growth – Q1 2021 vs Q1 2022 Marks 540% Upswing –
Driven by Diverse Marketplace Approach & Opportunity for Marketers to
Invest in Under-Represented Communities

HOUSTON, July 20, 2022 /PRNewswire/ — Direct Digital Holdings (Nasdaq: DRCT) announced today that its supply-side advertising platform, Colossus SSP, had a strong first quarter, with comparisons between Q1 2021 to Q1 2022 showing a 540 percent surge in revenue. This uptick comes on the heels of year-over-year revenue growing by 330 percent between 2020 and 2021, as well as a triple digit increase the previous year, with the platform’s revenue rising by 235 percent between 2019 and 2020. Leadership credits the dramatic growth to the company’s commitment to normalize diversity in the field of programmatic advertising – delivering multicultural and general market audiences at scale. In addition, it points to several brands living up to their promises to support under-represented communities in their media buys.

Direct Digital Holdings logo (PRNewsfoto/Direct Digital Holdings)

“Colossus SSP’s approach has always been one of inclusivity, bringing together a diverse set of audiences – Black, Hispanic, Asian, LGBTQ, and more – alongside general market, to serve as a one-stop-shop for advertisers who want to reach a cross-section of consumers,” said Lashawnda Goffin, CEO, Colossus SSP. “Not only has this allowed savvy marketers the opportunity to reach a vibrant range of consumers, but it has helped them increase investment in minority-owned media properties that have often been left out of the programmatic mix. Moreover, by putting their budgets to work to support multicultural voices, these brands are seeing remarkable results in meeting critical KPIs.”

The number of brands and media agencies tapping into Colossus SSP’s inclusive audience approach rose by 87 percent comparing Q1 2021 to Q1 2022, with clients such as Bayer, HP, and the NBA coming on board.

“At Bayer, we believe everyone should have the opportunity to live the healthiest life possible, and that we have a responsibility to make our vision of Health for All, Hunger for None a reality,” said Gary Guarnaccia, Head of Platform & Publisher Investment, Bayer Consumer Health, North America. “Partnering with Colossus SSP and their growing marketplace of diverse content and minority-owned publishers has enabled our in-house digital media buying team to expand our reach to consumers with important information about our healthcare products and brands, such as Aleve, Midol and One-A-Day.”

In lockstep with demand, in Q1 2022 Colossus SSP significantly expanded its publisher inventory supply. Currently Colossus SSP makes over approximately 90 billion impressions available each month with a diverse audience marketplace that includes over 13,000 sites and apps.

Blavity Inc, a market leader for Black media, reaching over 100 million millennials per month, began working with Colossus SSP in January 2020 and over the course of the following two years saw a 7-fold increase in revenues derived from the partnership.

“Colossus SSP has proven to be a valuable partner, one that has a deep understanding of publishers – especially multicultural publishers – as well as the media and marketing landscape at large,” said Orchid Richardson, Senior Vice President of Digital, Blavity Inc. “After two years of exponential growth, we are on track to see revenues from our relationship with Colossus SSP rise at a steady clip – if not outpace.”

“Colossus SSP’s rapid growth is a testament to its distinct approach to diversity, technology and the dynamic team that Lashawnda Goffin has been able to build,” said Mark Walker, CEO, Direct Digital Holdings. “Marketers are experiencing the benefits through multiple ROI metrics and subsequently publisher partners are experiencing significant growth in revenues. It’s a win-win situation.”

About Direct Digital Holdings
Direct Digital Holdings (Nasdaq: DRCT) brings state-of-the-art sell- and buy-side advertising platforms together under one umbrella company. The holding group’s Sell-side platform Colossus SSP offers advertisers of all sizes extensive reach within general market and multicultural media properties. Its operating companies Huddled Masses and Orange142 deliver significant ROI for middle market advertisers by providing data-optimized programmatic solutions at scale for businesses in sectors that range from energy to healthcare and travel to financial services. Direct Digital Holdings’ sell- and buy-side solutions manage approximately 70,000 clients monthly, generating over 90 billion impressions per month across display, CTV, in-app, and other media channels. The company has been named a top minority-owned business by The Houston Business Journal (“HBJ”).

About Colossus SSP
Part of Direct Digital Holdings (Nasdaq: DRCT), Colossus SSP is a leading custom supply-side platform (SSP) that delivers a diverse marketplace, enabling programmatic media buyers to connect with multicultural and general market audiences at scale. Colossus SSP’s consulting arm provides brands of all sizes with meaningful insights and actionable guidance for reaching curated audiences.  For more information, visit www.colossusmediassp.com.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/growth-of-direct-digital-holdings-colossus-ssp-reflects-strong-results-generated-for-multicultural–general-market-publishers-and-leading-brands-301590136.html

SOURCE Direct Digital Holdings

 


The GEO Group (GEO) – Maturity Wall Removed, But at What Cost?

Posted on by Admin

Wednesday, July 20, 2022

The GEO Group (GEO)
Maturity Wall Removed, But at What Cost?

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Maturity Wall. The GEO Group has entered into a series of proposed transactions with certain of its secured and unsecured creditors that will, if completed, comprehensively address the substantial majority of the Company’s debt maturity wall. This should remove a significant near-term concern of investors and GEO shares reacted as expected, rising 8.50% yesterday.

Details. Recall, GEO has $278 million of debt payments in 2023 and $1.77 billion of repayments in 2024. Although the operating environment has turned favorable, limited capital markets access makes it unlikely GEO would be able to refinance the debt as it came due. The proposed transactions push the maturity wall out far enough that we believe GEO should be able to successfully refinance any debt that remains outstanding….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.